本文選題：變應(yīng)性接觸性皮炎 + SEB��； 參考：《第三軍醫(yī)大學(xué)》2016年碩士論文

【摘要】：研究背景和目的外用糖皮質(zhì)激素(glucocorticoids,GC)作為多種皮膚病的治療手段已有較長(zhǎng)歷史。然而,在臨床工作中常發(fā)現(xiàn)許多炎癥性皮膚病患者長(zhǎng)期外用GC后出現(xiàn)GC療效下降,這種現(xiàn)象被稱(chēng)為GC的“快速減敏(tachyphylaxis)”或“快速耐受(acute tolerance)”。研究發(fā)生激素抵抗的機(jī)制對(duì)于改善外用GC療效至關(guān)重要。長(zhǎng)期外用GC的皮膚病如銀屑病、特應(yīng)性皮炎通常伴隨金黃色葡萄球菌定植,金黃色葡萄球菌能分泌或者代謝具有免疫原性的外毒素——細(xì)菌超抗原,如金黃色葡萄球菌腸毒素B(staphylococcal enterotoxin B,SEB)。SEB不需要抗原呈遞細(xì)胞加工,即能被T細(xì)胞識(shí)別,激活大量T細(xì)胞(大約占總T細(xì)胞的20%),導(dǎo)致TNF-α、TNF-β、IL-2和INF-γ等炎癥因子大量釋放,從而加重各種組織的炎性和過(guò)敏反應(yīng)。研究已經(jīng)發(fā)現(xiàn)SEB能誘導(dǎo)系統(tǒng)激素抵抗。我們前期實(shí)驗(yàn)結(jié)果顯示SEB可能上調(diào)皮炎局部糖皮質(zhì)激素受體β(glucocorticoid receptorβ,GRβ)表達(dá)介導(dǎo)激素抵抗,但SEB是否影響角質(zhì)形成細(xì)胞GRα核轉(zhuǎn)移尚不清楚,本研究將建立小鼠變應(yīng)性接觸性皮炎(allergic contact dermatitis,ACD)模型,觀察SEB是否抑制角質(zhì)形成細(xì)胞GRα核轉(zhuǎn)移,探討FKBP51和FKBP52表達(dá)是否影響SEB對(duì)GRα核轉(zhuǎn)移的作用,以及他克莫司是否能拮抗SEB對(duì)外用GC的抵抗作用,旨在提出SEB導(dǎo)致外用激素抵抗的新機(jī)制和新認(rèn)識(shí),為今后找到可能的治療靶點(diǎn)提供了新的實(shí)驗(yàn)依據(jù)。方法使用1%DNCB建立小鼠變應(yīng)性接觸性皮炎(allergic contact dermatitis,ACD)模型,采用HE染色檢測(cè)小鼠背部皮膚炎性細(xì)胞數(shù)變化;激光共聚焦定位GRα在小鼠角質(zhì)形成細(xì)胞中的分布;Western blot檢測(cè)GRα在小鼠角質(zhì)形成細(xì)胞胞漿和胞核的表達(dá);ELISA檢測(cè)各組IL-2、4、13和TNF-a炎癥因子的表達(dá);Real-Time PCR和Western blot分別檢測(cè)FK506結(jié)合蛋白51(FK506-binding protein 51,FKBP51)和FKBP52 m RNA和蛋白的表達(dá)。實(shí)驗(yàn)分2部分進(jìn)行探討:1)細(xì)菌超抗原SEB抑制小鼠角質(zhì)形成細(xì)胞糖皮質(zhì)激素受體核轉(zhuǎn)移作用及機(jī)制研究;2)他克莫司、FKBP51和FKBP52調(diào)控SEB小鼠角質(zhì)形成細(xì)胞糖皮質(zhì)受體核轉(zhuǎn)移障礙的作用及機(jī)制。結(jié)果1.與皮炎組相比,SEB處理皮炎組真皮內(nèi)炎性細(xì)胞顯著增加。與地塞米松處理組相比,SEB可減少地塞米松抗炎作用,SEB的抑制作用可被他克莫司拮抗;2.與皮炎組相比,地塞米松處理皮炎組GRα核/漿陽(yáng)性比值顯著增高。與地塞米松處理皮炎組相比,SEB可顯著降低SEB+地塞米松處理組GRα核/漿陽(yáng)性比值,但他克莫司可拮抗SEB,提高GRα核/漿陽(yáng)性比值。3.與皮炎組相比,地塞米松可顯著增加胞漿GRα蛋白表達(dá)。與地塞米松處理組相比,SEB可顯著增加胞漿GRα滯留量,減少GRα入核量。SEB對(duì)GRα核轉(zhuǎn)移抑制可被他克莫司部分拮抗。4.與皮炎組相比,地塞米松處理皮炎組IL-2、4、13和TNF-a炎癥因子顯著減少。與地塞米松處理組相比,SEB可顯著拮抗地塞米松對(duì)炎性因子的抑制作用,但他克莫司可拮抗SEB這一作用;5.與正常對(duì)照組相比,地塞米松處理組角質(zhì)形成細(xì)胞FKBP51明顯增高,而FKBP52無(wú)影響,提示地塞米松可能通過(guò)提高FKBP51表達(dá)負(fù)調(diào)控自身的抗炎作用。SEB處理后也顯著增加FKBP51表達(dá),而對(duì)FKBP52無(wú)影響,提示SEB導(dǎo)致的激素抵抗作用可能是通過(guò)上調(diào)FKBP51表達(dá)水平來(lái)實(shí)現(xiàn)的。而他克莫司處理后,可顯著降低SEB和地塞米松對(duì)FKBP51的上調(diào)作用,提示他克莫司抗炎作用可能部分是通過(guò)減少FKBP51表達(dá)實(shí)現(xiàn)的。全文結(jié)論1.SEB能減弱地塞米松對(duì)小鼠變應(yīng)性接觸性皮炎的抗炎作用;2.SEB誘導(dǎo)的激素抵抗與其阻礙角質(zhì)形成細(xì)胞GRα核轉(zhuǎn)移有關(guān);3.SEB誘導(dǎo)GRα核轉(zhuǎn)移障礙與其增加角質(zhì)形成細(xì)胞FKBP51表達(dá)有關(guān);4.他克莫司能恢復(fù)SEB減弱的激素療效,機(jī)制與其下調(diào)SEB誘導(dǎo)的FKBP51表達(dá)和逆轉(zhuǎn)SEB介導(dǎo)的GRα核轉(zhuǎn)移障礙有關(guān)。
[Abstract]:Background and objective glucocorticoids (GC) has a long history as a treatment for multiple dermatosis. However, in clinical work, many patients with inflammatory dermatoses are often found to have a decrease in GC after long-term external use of GC. This phenomenon is called "rapid desensitization (tachyphylaxis)" or "fast tolerance (AC)" (AC). Ute tolerance) ". The study of the mechanism of hormone resistance is essential to improve the efficacy of external GC. Long-term external use of GC skin diseases such as psoriasis, atopic dermatitis usually accompanied by Staphylococcus aureus colonization, Staphylococcus aureus can secrete or metabolize an immunogenic exotoxin - bacterial superantigen, such as golden yellow globules The bacterial enterotoxin B (staphylococcal enterotoxin B, SEB).SEB does not need antigen presenting cell processing, that is, it can be identified by T cells and activates a large number of T cells (about 20% of the total T cells), leading to a large release of inflammatory factors such as TNF- a, TNF- beta, IL-2 and gamma, which aggravates the inflammatory and allergic reactions of various tissues. Our preliminary results show that SEB may mediate hormone resistance in local glucocorticoid receptor beta (glucocorticoid receptor beta, GR beta), but whether SEB affects GR alpha nuclear transfer in keratinocytes is not clear. This study will establish a mouse allergic contact dermatitis (allergic contact dermatitis, ACD). To observe whether SEB inhibits keratinocyte GR alpha nuclear transfer, and explores whether the expression of FKBP51 and FKBP52 affects the effect of SEB on GR alpha nuclear transfer, and whether tacrolimus can antagonize the resistance of SEB to external GC, and aims to propose a new mechanism and new understanding of SEB leading to the resistance of external use hormone, and to provide a potential therapeutic target for the future. New experimental basis. Methods the model of mouse allergic contact dermatitis (allergic contact dermatitis, ACD) was established by 1%DNCB. The number of inflammatory cells in the back skin of mice was detected by HE staining, and the distribution of GR alpha in the keratinocytes of mice was localized by laser confocal microscopy; Western blot detected GR a in the cytoplasm and cell of mouse keratinocytes. The expression of IL-2,4,13 and TNF-a inflammatory factors were detected by ELISA; Real-Time PCR and Western blot were used to detect the expression of FK506 binding protein 51 (FK506-binding protein 51, FKBP51) and FKBP52 proteins and proteins. The experiment was divided into 2 parts: 1) bacterial superantigen was used to inhibit the corticosteroid receptor nucleus of mouse keratinocytes Transfer and mechanism study; 2) tacrolimus, FKBP51 and FKBP52 regulated the effect and mechanism of the nuclear transfer disorder in the keratinocytes of SEB mice. Results compared with the dermatitis group 1., the dermatitis intradermal inflammatory cells in the dermatitis group were significantly increased. Compared with the dexamethasone treatment group, SEB could reduce the anti-inflammatory effect of dexamethasone and the inhibition of SEB. The effect can be antagonized by tacrolimus; 2. compared with dermatitis, the positive ratio of GR alpha nucleus / pulp in dexamethasone treated dermatitis group was significantly higher. Compared with dexamethasone treated dermatitis group, SEB could significantly reduce the GR alpha core / pulp positive ratio of SEB+ dexamethasone treatment group, but tacrolimus can antagonize SEB and improve the GR alpha core / pulp positive ratio.3. compared with dermatitis group. Dexamethasone significantly increased the expression of cytoplasmic GR alpha protein. Compared with the dexamethasone treatment group, SEB significantly increased the retention of cytoplasmic GR a, and reduced the GR alpha nucleation.SEB on GR alpha nuclear transfer inhibition could be partially antagonized by tacrolimus in.4. with the dermatitis group, and dexamethasone treated Pi Yanzu IL-2,4,13 and TNF-a inflammatory factors significantly. Compared with the pine treatment group, SEB could significantly antagonize the inhibition of dexamethasone on inflammatory factors, but tacrolimus could antagonize the effect of SEB. 5. compared with the normal control group, the keratinocyte FKBP51 in the dexamethasone treatment group was significantly higher, while FKBP52 had no effect, suggesting that dexamethasone might improve the anti inflammatory activity of the FKBP51 expression by increasing the negative regulation of the FKBP51 expression. .SEB treatment also significantly increased the expression of FKBP51, but had no effect on FKBP52, suggesting that SEB induced hormone resistance may be achieved by up regulation of FKBP51 expression. And tacrolimus can significantly reduce the effect of SEB and dexamethasone on FKBP51, suggesting that the anti inflammatory effect of the camosi may be partly by reducing FKBP5. 1 expression is realized. Conclusion 1.SEB can weaken the anti-inflammatory effect of dexamethasone on allergic contact dermatitis in mice; 2.SEB induced hormone resistance is related to its obstruction of keratinocyte GR alpha nuclear transfer; 3.SEB induced GR alpha metastasis is related to the increase of FKBP51 surface of keratinocytes; and tacrolimus can restore the excitation of SEB weakening. The mechanism of its effect is related to its down-regulation of SEB induced FKBP51 expression and the reversal of SEB mediated GR alpha nuclear transfer dysfunction.
【學(xué)位授予單位】：第三軍醫(yī)大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類(lèi)號(hào)】：R751

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 鄭敏,楊宏杰;陰虛患者糖皮質(zhì)激素受體改變及意義[J];中國(guó)病理生理雜志;2000年10期

2 楊宏杰,鄭敏;陽(yáng)虛患者糖皮質(zhì)激素受體改變及意義[J];中國(guó)病理生理雜志;2000年10期

3 李琳蕓;王昌富;;糖皮質(zhì)激素治療抵抗與糖皮質(zhì)激素受體分子表達(dá)異常的關(guān)系[J];國(guó)際檢驗(yàn)醫(yī)學(xué)雜志;2006年10期

4 楊珍;湯靜燕;繆艷;蔣黎明;;特發(fā)性血小板減少性紫癜患兒糖皮質(zhì)激素受體研究[J];臨床兒科雜志;2006年10期

5 于肇英;;腦內(nèi)糖皮質(zhì)激素受體與鹽皮質(zhì)激素受體的研究[J];醫(yī)學(xué)研究通訊;1987年08期

6 黃宗海,高瀚,徐仁寶;外周血白細(xì)胞糖皮質(zhì)激素受體測(cè)定方法的改進(jìn)[J];第二軍醫(yī)大學(xué)學(xué)報(bào);1989年01期

7 唐尚國(guó);糖皮質(zhì)激素受體新進(jìn)展[J];國(guó)外醫(yī)學(xué).內(nèi)分泌學(xué)分冊(cè);1989年03期

8 蔡紹暉;葉松柏;;糖皮質(zhì)激素受體的調(diào)節(jié)及其意義[J];四川生理科學(xué)雜志;1989年04期

9 高勇義;糖皮質(zhì)激素受體在內(nèi)分泌領(lǐng)域內(nèi)的研究進(jìn)展[J];國(guó)外醫(yī)學(xué).內(nèi)分泌學(xué)分冊(cè);1990年02期

10 汪云利;楊平;;淋巴細(xì)胞糖皮質(zhì)激素受體測(cè)定[J];西南國(guó)防醫(yī)藥;1991年02期

相關(guān)會(huì)議論文 前10條

1 楊珍;湯靜燕;繆燕;蔣黎明;;特發(fā)性血小板減少性紫癜患兒糖皮質(zhì)激素受體的研究[A];2006（第三屆）江浙滬兒科學(xué)術(shù)會(huì)議暨浙江省兒科學(xué)術(shù)年會(huì)論文匯編[C];2006年

2 楊珍;湯靜燕;繆燕;蔣黎明;;特發(fā)性血小板減少性紫癜患兒糖皮質(zhì)激素受體的研究[A];中華醫(yī)學(xué)會(huì)第十四次全國(guó)兒科學(xué)術(shù)會(huì)議論文匯編[C];2006年

3 向潤(rùn)娥;湯靜燕;繆艷;羅長(zhǎng)纓;潘慈;陳靜;董璐;周敏;黃俊;;兒童急性淋巴細(xì)胞白血病糖皮質(zhì)激素受體基因變異研究[A];中國(guó)抗癌協(xié)會(huì)第七屆全國(guó)小兒腫瘤學(xué)術(shù)會(huì)議論文匯編[C];2007年

4 苗慧;翟曉文;王宏勝;陸鳳娟;高怡瑾;羅飛宏;;糖皮質(zhì)激素受體基因多態(tài)性與兒童急性淋巴細(xì)胞白血病關(guān)系的研究[A];中華醫(yī)學(xué)會(huì)第十七次全國(guó)兒科學(xué)術(shù)大會(huì)論文匯編（上冊(cè)）[C];2012年

5 王笑秋;;地塞米松上調(diào)人胚肺成纖維細(xì)胞中糖皮質(zhì)激素受體的表達(dá)[A];中華醫(yī)學(xué)會(huì)第十五次全國(guó)兒科學(xué)術(shù)大會(huì)論文匯編（上冊(cè)）[C];2010年

6 馬鈞;景炳文;劉志民;;多臟器功能衰竭病入糖皮質(zhì)激素受體變化探討[A];中華醫(yī)學(xué)會(huì)全國(guó)第五次急診醫(yī)學(xué)學(xué)術(shù)會(huì)議論文集[C];1994年

7 朱曉燕;劉書(shū)娟;劉宇健;王長(zhǎng)楠;王山;刁飛;盧建;徐仁寶;倪鑫;;糖皮質(zhì)激素在炎癥中的作用及其分泌調(diào)節(jié)[A];中國(guó)生理學(xué)會(huì)第十一屆張錫鈞基金全國(guó)青年優(yōu)秀生理學(xué)學(xué)術(shù)論文交流及評(píng)獎(jiǎng)會(huì)議綜合摘要[C];2011年

8 吳永恒;方之揚(yáng);杜風(fēng)鳴;;燒傷早期狗外周血淋巴細(xì)胞糖皮質(zhì)激素受體的研究[A];全國(guó)第三屆燒傷外科學(xué)術(shù)交流會(huì)議論文摘要[C];1991年

9 徐永紅;劉榮玉;;活化蛋白1及糖皮質(zhì)激素受體在慢性阻塞性肺疾病中的表達(dá)及意義[A];中華醫(yī)學(xué)會(huì)第五次全國(guó)哮喘學(xué)術(shù)會(huì)議暨中國(guó)哮喘聯(lián)盟第一次大會(huì)論文匯編[C];2006年

10 劉凌云;曾勉;謝燦茂;嚴(yán)英碩;王輝;高景輝;;慢性阻塞性肺疾病患者氧化應(yīng)激狀態(tài)及其與糖皮質(zhì)激素受體水平相關(guān)性的研究[A];中華醫(yī)學(xué)會(huì)第七次全國(guó)呼吸病學(xué)術(shù)會(huì)議暨學(xué)習(xí)班論文匯編[C];2006年

相關(guān)重要報(bào)紙文章 前2條

1 冉新澤;創(chuàng)傷應(yīng)激研究獲得新突破[N];中國(guó)醫(yī)藥報(bào);2007年

2 胥曉琦;2006年中國(guó)中西醫(yī)結(jié)合學(xué)會(huì)科學(xué)技術(shù)獎(jiǎng)獲獎(jiǎng)項(xiàng)目綜述[N];中國(guó)中醫(yī)藥報(bào);2007年

相關(guān)博士學(xué)位論文 前9條

1 毛sビ，

本文編號(hào)：2103796